Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Update

Iterum Therapeutics plc (NASDAQ:ITRM) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 2,530,000 shares, a growth of 1,082.8% from the October 15th total of 213,900 shares. Approximately 11.5% of the company’s shares are sold short. Based on an average trading volume of 2,330,000 shares, the short-interest ratio is currently 1.1 days.

Iterum Therapeutics Stock Down 9.8 %

Shares of ITRM stock traded down $0.14 on Thursday, reaching $1.29. 845,463 shares of the stock were exchanged, compared to its average volume of 955,001. The stock has a market cap of $29.30 million, a P/E ratio of -0.72 and a beta of 2.25. The firm has a 50 day moving average of $1.15 and a two-hundred day moving average of $1.24. Iterum Therapeutics has a 1-year low of $0.76 and a 1-year high of $2.50.

Iterum Therapeutics (NASDAQ:ITRM) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.22. On average, equities research analysts predict that Iterum Therapeutics will post -1.19 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Iterum Therapeutics in a research report on Tuesday, September 10th.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.